MAPT and Alzheimer disease: In AD, reduced amyloid-beta 42 (Aβ42), increased phosphorylated tau, and elevated neurogranin in CSF collectively reflect the early presence of plaques, tau pathology, and synaptic loss, which are key indicators before cognitive symptoms fully develop [363].